Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION.

6510 Background: In the randomized phase III DASISION trial of dasatinib v IM in newly diagnosed CML-CP, dasatinib showed higher and faster rates of complete cytogenetic response (CCyR) and major m...